BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $4 from $9 and keeps an Underperform rating on the shares following what the firm says was “another disappointing quarter,” headlined by a $35M reduction to sales guidance. Myriad has continued to experience headwinds and “the company has not managed to turn the page,” says the analyst, who updated estimates accounting for continued headwinds and revised guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target lowered to $7 from $16 at Morgan Stanley
- Myriad Genetics price target lowered to $9 from $12.50 at Piper Sandler
- Hold Rating Maintained for Myriad Genetics Amid Revenue Cuts and Strategic Uncertainty
- Myriad Genetics Faces Challenges Amid Prenatal Testing Growth
- Myriad Genetics downgraded to Peer Perform from Outperform at Wolfe Research